Philip Scheltens, Everard (Jort) Vijverberg on Aducanumab Still Needs to Prove Itself, Researchers Say
COMMENT Much has been said on aducanumab already and, as in any scientific debate, opinions differ widely. Unfortunately, as was evident from the FDA hearing, the debate has become polarized, as if it were politics. This is never beneficial to any debate. This ...